Astraveus Leads the Way in CAR-T Cell Production Technology
Astraveus SAS, a notable name in cell therapy innovation, has made a groundbreaking announcement regarding the production of CAR-T cells. This has been accomplished using an advanced microfluidic technology integrated into their newly developed Lakhesys Benchtop Cell Factory. This pioneering approach is set to transform the landscape of cell therapy by making treatments more accessible and affordable.
The Innovative Lakhesys Benchtop Cell Factory
The Lakhesys Benchtop Cell Factory is a fully automated system that integrates the entire process of CAR-T cell manufacturing. It incorporates sophisticated analytics and microfluidic technology, which streamlines production, minimizes cell stress, and optimizes cell quality. This method drastically reduces manufacturing costs and accelerates the production process significantly.
Optimal Processing and Efficiency
With the Lakhesys system, production times are remarkably short, taking only 26 hours. This efficiency is complemented by the system’s ability to handle scalability from pre-clinical to commercial stages without compromising on quality. The capacity to produce at various scales allows for a transition that could potentially revolutionize the field of cell therapy.
Comments from Leadership
Jérémie Laurent, CEO of Astraveus, expressed his enthusiasm regarding this achievement. He stated, "We are incredibly excited to see our team's efforts come to fruition. For the first time, CAR-T cells have been successfully produced using our fully automated end-to-end microfluidic system, which serves as proof of concept for our sophisticated benchtop cell factory. Our goal has always been to miniaturize complex processes, and we have remarkably achieved this.
The Future of Cell Therapies
Prof. Jérôme Larghero, who is part of the Scientific Advisory Board at Astraveus, elaborated on the implications of this innovation. He noted, "By making production more scalable, cheaper, and decentralized, we are laying a significant foundation for cell therapies to become the new standard of care. The Lakhesys system is just the beginning, with enormous potential to revolutionize production for the benefit of many patients worldwide."
Commitment to Revolutionizing Cell Treatment Accessibility
Founded in 2016, Astraveus aims to make high-quality cell therapies available to a larger audience. The company emerged from a dynamic research environment, focusing on integrating innovation in bioprocessing at the cellular level. Using microfluidic technology, they strive to provide solutions that are not just efficient but also economically sustainable. With aspirations of enhancing health outcomes, Astraveus is committed to enabling access to cutting-edge therapies.
About Astraveus
Astraveus is a life science company that focuses on maximizing the quality of cell therapies while significantly reducing costs. Through the unique Lakhesys Benchtop Cell Factory, the company emphasizes process optimization and scalability. With its strategic foundation, Astraveus is poised to make a significant impact in the field of cell therapy and aims to transform the way these therapies are developed and manufactured.
Frequently Asked Questions
1. What is the Lakhesys Benchtop Cell Factory?
The Lakhesys Benchtop Cell Factory is a novel automated system designed to integrate the production and analysis of CAR-T cells using microfluidic technology.
2. How does this new technology affect manufacturing costs?
This technology significantly reduces manufacturing costs by streamlining the process and optimizing resource use.
3. What are CAR-T cells?
CAR-T cells are a type of immunotherapy that involves modifying a patient's T-cells to better attack cancer cells.
4. Who is leading Astraveus?
The company is led by Jérémie Laurent, who serves as its Chief Executive Officer.
5. What are the future plans for Astraveus?
Astraveus plans to further enhance its technology, making cell therapies more accessible and setting new standards in healthcare.
